Migraine is a complicated, multifactoral neurological disorder that represents one of the most common causes of disability in the world. It is characterized by unilateral, pulsating headaches and is accompanied by various symptoms such as nausea, vomiting, increased sensitivity to motion, light, sounds, smells and food. Approximately one third of migraine patients experience neurological deficits, such as cortical pertubations, which is called a migraine aura. Migraine patophysiology is complicated and not yet fully understood. According to current knowledge, the main event in migraine patophysiology is activation and sesitisation of the trigeminovascular system which results in typical migraine headaches. Migraine treatment can be focused towards diminishing pain (acute/abortive) or to prevent the attack altogether. Acute therapy includes analgesics, antiemetics, ergot alcaloids and triptans; whereas preventive therapy includes antihypertensives, antidepressants, antiepileptics, non-steroid antiinflammatory drugs, onabotulinum toxin A and various non-pharmacological approaches. Certain patients that have a high frequency or high intensity headaches require both therapeutic strategies. Preventive drugs are often combined with other therapeutic options and are a part of the wholesale individualised therapy approach. Preventive treatment is used to reduce the frequency of migraine attacks, their severity and duration, to improve the response to acute therapy and to increase functionality and decrease disability in suffering patients. Furthemore, effective treatment leads to reduced healthcare costs. Today, triptans represent the main antimigrenic therapy line that do not show satisfying responses in a lot of paitients, which warrants futher research into other neuropeptides and receptors discovered to be a part of the migraine pathophysiology.